Biologics in Severe Asthma: Optimizing Therapeutic Selection and Patient Outcomes

To participate in this activity, please:

Welcome to this audiovisual activity on the pathophysiologic basis and use of biologic therapy for the treatment of patients with severe asthma. This case-based activity focuses on considerations, including phenotypes and biomarkers, in individualizing treatment with the 5 monoclonal antibodies currently approved for severe asthma in the United States. The role of shared decision-making is discussed as an approach to individualizing therapy and improving patient outcomes. Clinical criteria for assessing treatment response to biologic therapy and how to modify therapy when needed are also discussed.

Course Credit:

0.75 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-12-14
Closes: 2021-12-14

Target Audience:

This activity was developed for pulmonologists, allergists, immunologists, primary care physicians, and other healthcare professionals involved in the care of patients with severe asthma.

This activity is supported by an independent educational grant from Novartis Pharmaceuticals Corporation.
  • Reynold A. Panettieri, Jr, MD

    Vice Chancellor, Translational Medicine and Science
    Director, Rutgers Institute for Translational Medicine and Science
    Professor of Medicine, Rutgers University
    New Brunswick, New Jersey
    Emeritus Professor of Medicine, University of Pennsylvania

Learning Objectives

  • Discuss the latest evidence regarding the pathophysiology of severe asthma
  • Explain the clinical implication of the latest scientific developments in the area of biologic therapies for the management of severe asthma
  • Differentiate biologic therapies currently available for the management of patients with severe asthma
  • Implement biologic therapy for a patient with severe asthma taking into account the latest available data and genetic factors

Faculty Disclosures

Reynold A. Panettieri, Jr, MD

Advisory Board: AstraZeneca, Equillium, RIFM

Research Support: AstraZeneca, Genentech, Johnson and Johnson, Maven, Medimmune, Novartis, Optikira, RIFM

Speakers Bureau: AstraZeneca, Genentech, Regeneron, Sanofi


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)

No significant relationship to disclose


Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.